BAAM
HZNP

Baker Avenue Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Baker Avenue Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28
Closed -$3.24K – 1607
2023
Q3 		$3.24K Buy
28
+3
+12% +$322 ﹤0.01% 1041
2023
Q2 		$2.57K Hold
25
– – ﹤0.01% 939
2023
Q1 		$2.73K Sell
25
-22
-47% -$2.43K ﹤0.01% 941
2022
Q4 		$5.35K Buy
+47
New +$3.9K ﹤0.01% 811

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Baker Avenue Asset Management's HZNP Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 28 shares — an estimated $3.24K sold.

Baker Avenue Asset Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $5.35K in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 28 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $3.24K.
  • Baker Avenue Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.35K in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.